MAIA Biotechnology Files 8-K for Financials and Exhibits
Ticker: MAIA · Form: 8-K · Filed: Mar 25, 2024 · CIK: 1878313
| Field | Detail |
|---|---|
| Company | Maia Biotechnology, INC. (MAIA) |
| Form Type | 8-K |
| Filed Date | Mar 25, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $1,445,000, $4,950,000, $745,250 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, exhibits
TL;DR
MAIA Bio filed an 8-K for financials, nothing major to see here.
AI Summary
On March 25, 2024, MAIA Biotechnology, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or other significant business updates detailed in the provided text.
Why It Matters
This filing indicates routine financial reporting and exhibit submission, providing transparency for investors regarding the company's financial status and related documentation.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for financial statements and exhibits, indicating routine reporting rather than a significant event.
Key Players & Entities
- MAIA Biotechnology, Inc. (company) — Registrant
- March 25, 2024 (date) — Date of earliest event reported
- 001-41455 (other) — Commission File Number
- 444 West Lake Street, Suite 1700 (address) — Principal executive offices
- Chicago, IL 60606 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing by MAIA Biotechnology, Inc.?
The primary purpose of this 8-K filing is to report financial statements and exhibits, as indicated by the 'ITEM INFORMATION: Financial Statements and Exhibits' section.
On what date was this 8-K report filed or effective?
The report was filed as of March 25, 2024, and the date of the earliest event reported is also March 25, 2024.
What is MAIA Biotechnology, Inc.'s state of incorporation and fiscal year end?
MAIA Biotechnology, Inc. is incorporated in Delaware and its fiscal year ends on December 31.
What is the Commission File Number for MAIA Biotechnology, Inc.?
The Commission File Number for MAIA Biotechnology, Inc. is 001-41455.
Where are MAIA Biotechnology, Inc.'s principal executive offices located?
MAIA Biotechnology, Inc.'s principal executive offices are located at 444 West Lake Street, Suite 1700, Chicago, IL 60606.
Filing Stats: 518 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-03-25 16:08:05
Key Financial Figures
- $0.0001 — f the Company's common stock, par value $0.0001 per share (the "Common Stock") issuable
- $1,445,000 — ht & Co., dated February 14, 2024, from $1,445,000 to $4,950,000 and filed a prospectus su
- $4,950,000 — d February 14, 2024, from $1,445,000 to $4,950,000 and filed a prospectus supplement (the
- $745,250 — tock having an aggregate sales price of $745,250 under the Sales Agreement. A copy of th
Filing Documents
- d802381d8k.htm (8-K) — 25KB
- d802381dex51.htm (EX-5.1) — 11KB
- g802381g0325001415766.jpg (GRAPHIC) — 4KB
- 0001193125-24-076482.txt ( ) — 169KB
- maia-20240325.xsd (EX-101.SCH) — 3KB
- maia-20240325_lab.xml (EX-101.LAB) — 18KB
- maia-20240325_pre.xml (EX-101.PRE) — 11KB
- d802381d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 5.1 Opinion of Sheppard Mullin Richter & Hampton LLP 23.1 Consent of Sheppard Mullin Richter & Hampton LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: March 25, 2024 MAIA BIOTECHNOLOGY, INC. By: /s/ Vlad Vitoc Name: Vlad Vitoc Title: Chief Executive Officer 3